<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766076</url>
  </required_header>
  <id_info>
    <org_study_id>HS1258</org_study_id>
    <nct_id>NCT01766076</nct_id>
  </id_info>
  <brief_title>Atorvastatin for HAART Suboptimal Responders</brief_title>
  <official_title>Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaccine and Gene Therapy Institute, Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <authority>Uganda: National Council for Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesise that atorvastatin changes immune activation among HAART-treated adults with
      suboptimal cluster cell differentiation 4 (CD4) recovery by 25%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have previously shown that up to 40% of HAART-treated adults have
      suboptimal CD4 recovery despite viral suppression. The investigators have also shown that
      immune activation and exhaustion are significantly higher among patients that do not exhibit
      satisfactory rise in CD4 counts despite viral suppression (suboptimal responders); when
      compared with their counterparts with viral suppression and satifactory CD4 count recovery
      (optimal responders). Given that atorvastatin changes immune activation in this pilot study,
      then larger studies can be done to understand its effect on CD4 count increase among
      suboptimal responders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Immune activation was measured by co-expression of CD38 and HLADR on CD4 T-cells (CD4+CD38+HLADR+) Mean percentage change at 12 weeks was calculated</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acquired Immune Deficiency Syndrome Virus</condition>
  <arm_group>
    <arm_group_label>atorvastatin, Lipitor®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>atorvastatin, Lipitor®</intervention_name>
    <description>PBMC collected for immune activation assays using flowcytometry</description>
    <arm_group_label>atorvastatin, Lipitor®</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lipitor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBMC collected for immune activation assays using flowcytometry</description>
    <arm_group_label>atorvastatin, Lipitor®</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>atorvastatin placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        List of inclusion Criteria: HIV-infected adults on antiretroviral therapy for at least 6
        years with sustained viral suppression (viral load&lt;400 copies), and CD4 increase below 300
        cells (difference between current and baseline CD4 count).

        List of exclusion Criteria: History of an opportunistic infection within the previous six
        months, Pregnancy, History of myositis, History of ingestion of lipid-lowering agents at
        the baseline visit, Use of therapeutic agents known to have substantial drug-drug
        interactions with statins, and individuals on PI-containing HAART
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damalie Nakanjako, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <removed_countries>
    <country>Uganda</country>
  </removed_countries>
  <reference>
    <citation>Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker CF, Sklar P, Bavaro M, Tasker S, Follmann D, Maldarelli F. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011 Mar 15;203(6):756-64. doi: 10.1093/infdis/jiq115. Epub 2011 Feb 15.</citation>
    <PMID>21325137</PMID>
  </reference>
  <reference>
    <citation>Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011 Feb 8;11:43. doi: 10.1186/1471-2334-11-43.</citation>
    <PMID>21299909</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 20, 2015</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <firstreceived_results_date>July 17, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>College of Health Sciences</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>immune activation</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>immune exhaustion</keyword>
  <keyword>adults</keyword>
  <keyword>Africa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>30 participants were recruited from the Infectious Diseases Institute research cohort (single site) and followed up for 12 weeks, 4 weeks wash out period and 12 weeks after cross over of treatment assignment</recruitment_details>
      <pre_assignment_details>Participants were selected if they had sustained viral suppression for 7 years and CD4 increases below 300 cells/ul</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin First, Then Placebo</title>
          <description>Intervention is atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
PBMC were collected for immune activation assays using flowcytometry
'atorvastatin, Lipitor®': PBMC collected for immune activation assays using flowcytometry</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Atorvastatin</title>
          <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC were collected for immune activation assays using flowcytometry
Placebo: PBMC were collected for immune activation assays using flowcytometry</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin First, Then Placebo</title>
          <description>Intervention is atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
PBMC will be collected for immune activation assays using flowcytometry
'atorvastatin, Lipitor®': PBMC were collected for immune activation assays using flowcytometry</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Atorvastatin</title>
          <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
Placebo: PBMC were collected for immune activation assays using flowcytometry</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41" lower_limit="40" upper_limit="50"/>
                <measurement group_id="B2" value="47" lower_limit="43" upper_limit="51"/>
                <measurement group_id="B3" value="46" lower_limit="40" upper_limit="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Uganda</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>CD4 T-cell activation</title>
          <units>percenatage of activated CD4 T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4.2" lower_limit="3.7" upper_limit="6.2"/>
                <measurement group_id="B2" value="2.9" lower_limit="2.9" upper_limit="5.0"/>
                <measurement group_id="B3" value="4.2" lower_limit="1.5" upper_limit="8.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily</title>
        <description>Immune activation was measured by co-expression of CD38 and HLADR on CD4 T-cells (CD4+CD38+HLADR+) Mean percentage change at 12 weeks was calculated</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>There was no cross-over or carry-over effect (the sequence did not matter), so we present data for 30 patients for their 12 weeks exposure to atorvastatin</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
PBMC were collected for immune activation assays using flowcytometry
'atorvastatin, Lipitor®': PBMC were collected for immune activation assays using flowcytometry</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
Placebo: PBMC were collected for immune activation assays using flowcytometry</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily</title>
            <description>Immune activation was measured by co-expression of CD38 and HLADR on CD4 T-cells (CD4+CD38+HLADR+) Mean percentage change at 12 weeks was calculated</description>
            <units>percentage change in activated T-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60" lower_limit="50" upper_limit="68"/>
                  <measurement group_id="O2" value="21" lower_limit="2" upper_limit="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Mann Whitney test was used for nonparametric variables</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks on study drug, 4 weeks wash out, then 12 weeks of placebo</time_frame>
      <desc>No serious adverse event reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin First, Then Placebo</title>
          <description>Intervention is atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
PBMC were collected for immune activation assays using flowcytometry
'atorvastatin, Lipitor®': PBMCwere collected for immune activation assays using flowcytometry</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then Atorvastatin</title>
          <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC wiere collected for immune activation assays using flowcytometry
Placebo: PBMC were collected for immune activation assays using flowcytometry</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>3 myalgias were reported in atorvastatin and placebo groups</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint pains</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>backache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>right forearm pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Damalie Nakanjako</name_or_title>
      <organization>Makarere University</organization>
      <phone>41407000 ext 249</phone>
      <email>dnakanjako@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
